What You Should Know
- For many people awaiting CAR T-Cell Therapy, radiation (RT) or low-dose chemo keeps lymphoma in check, preserves strength, and—especially with RT—may prime the immune system to hit harder at infusion.
- The best evidence so far says: choose the bridge that controls disease quickly, is safe, and doesn’t delay CAR T-Cell infusion.
- Studies consistently report manageable toxicity and no excess in severe CAR T-Cell toxicities attributable to bridging itself. The bigger safety wins are symptom relief (pain, bleeding, mass effect) and avoiding disease-related decompensation that could derail eligibility.
Bridging therapies are short-term treatments designed to keep the disease under control while your CAR T-Cells are being engineered. In some cases, they may even do more than buy time; they can set the stage for CAR T-Cell Therapy to work more effectively. The NCCN patient guideline for DLBCL explicitly lists “CAR T-Cell Therapy with bridging therapy as needed” and outlines options in this waiting period.
Read MoreBridging Through Radiation Therapy
Modern radiation is quick and practical during the bridge window, serving as an important tool during waiting periods. Radiation therapy, or radiotherapy, involves delivering a high dose of X-rays to a specific area of the body where the disease is present.For patients presenting with pain or compressive masses, short courses (referred to as hypofractionation) can shrink tumors, relieve symptoms, and reduce steroid needs, often within days. Multi-center series report good tolerability and low added toxicity when radiation is delivered between cell collection and CAR T-Cell Therapy.
Several groups suggest a biologic synergy when giving radiation before CAR T-Cell Therapy. It’s been shown that it can cause immunogenic tumor cell death and release tumor antigens into circulation, translating into a better recognition by the new engineered cells when they are infused.
“The tumor antigens are released because of the radiation,” starts Dr. Ayyappan. “They circulate in the blood, and once your CAR-T Cells are infused, they are able to then identify some of these tumor antigens. So when they find the cancer, they’re even more effective.”
A large multi-center analysis of bridging radiotherapy (Br-RT) concluded it was well tolerated, and exploratory signals tied comprehensive RT to better results. A 2024 Blood Advances study testing low-dose, fractionated RT also described systemic responses: tumor shrinkage beyond the radiation field when used around CAR T-Cell Therapy.
Not Everyone Can Receive Radiation: Bridging Chemotherapy
If the disease is too widespread for focused radiation, or there’s no single “problem area,” the bridging therapy still can be offered, often using low-intensity chemotherapy. The goal is disease control with minimal baggage: tamp the cancer down without suppressing the very immune cells you’re counting on or adding organ stress before conditioning chemo. Reviews and center series show this approach can stabilize disease and maintain overall health to reach infusion.
Dr. Ayyappan adds that “you’re not trying to cure or get rid of the cancer, just control the disease so that when the CAR T-Cells are infused, they will do the job, they will get in, find the cancer and cure.”
Can CAR T-Cell Infusion Be Delayed Due To Side Effects of Bridging Therapy?
The short answer is yes, it can. However, one study evaluated this question by comparing the time to receive infusion following bridging therapy in those who had bridging therapy versus those who did not.
They found that there was no significant difference between groups, with an average of 29 vs. 28 days, respectively. Interestingly, patients who received bridging therapy with full-intensity chemo were more likely to present delays in receiving CAR -T-Cell infusion. It justifies why clinicians prescribe mild “bridging” or low-dose chemotherapy for this setting of patients.
In real-world data, bridging rarely causes treatment to be abandoned; instead, it allows more patients to reach infusion safely.
Questions To Ask Doctors
- Do I need bridging therapy before my CAR T-Cell infusion?
- What are the primary goals of bridging therapy in my case—controlling the lymphoma, relieving symptoms, helping CAR T-Cells work better, or something else?
- What are the main side effects or risks I should be aware of with bridging therapy?
- What symptoms or warning signs during bridging therapy should make me contact my care team right away?
- Are there supportive measures (nutrition, physical therapy, medications) to make bridging therapy easier to tolerate?
- How might bridging therapy affect the chances of my CAR T-Cell treatment working effectively?
Learn more about SurvivorNet's rigorous medical review process.
